期刊文献+

伊班膦酸钠联合化疗治疗骨转移瘤的临床观察 被引量:1

Therapeutic effect of ibandronate combined with chemotherapy on bone metastasis
在线阅读 下载PDF
导出
摘要 目的观察伊班膦酸钠联合化疗治疗骨转移瘤的临床效果。方法80例患者分为2组,即联合治疗组(伊班膦酸钠+化疗)和化疗组,伊班膦酸钠4mg+生理盐水500ml静滴,至少2h以上,每4周重复1次,化疗每3-4周重复1个周期,治疗2个周期后评价治疗效果。结果联合治疗组止痛、活动能力的改善及骨转移病灶的有效率分别为82.5%、62.5%、45%,均优于单纯化疗组(P〈0.05)。结论伊班膦酸钠联合化疗治疗骨转移瘤疗效好,毒副作用可以耐受。 Objective To evaluate the efficacy of combined therapy of ibandronate and chemotherapy for cancer patients with bone metastasis. Methods All 80 patients with bone metastasis received ibandronate combined with chemotherapy or chemotherapy alone. The intravenous infusion of 4 mg ibandronate was repeated every 4 weeks. Chemotherapy was administered every 3 or 4 weeks. The therapeutic efficacy was evaluated after 2 circles of chemotherapy. Results The response rate of pain relief, improving activity of daily living and managing bone metastasis focus was 82.5%, 62.5%, 45% respectively in ibandronate combined with chemotherapy, and 52.5% , 40% , 22.5% in chemotherapy, with significant difference between the 2 therapies ( P 〈0.05). Conclusion Combined therapy of ibandronate and chemotherapy is effective in treating cancer patients with bone metastasis and is well tolerated.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2006年第18期1903-1905,共3页 Journal of Third Military Medical University
关键词 骨转移 伊班膦酸钠 化学疗法 bone metastasis ibandronate chemotherapy
  • 相关文献

参考文献6

  • 1FIRKIN F,SEYMOUR J F,WATSON A M,et al.Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy[J].Br J Haematol,1996,94(3):486 -492.
  • 2NEUDERT M,FISCHER C,KREMPIEN B,et al.Site-specific human breast cancer (MDA-MB-231) metastases in nude rats:model characterisation and in vivo effects of ibandronate on tumour growth[J].Int J Cancer,2003,107(3):468 -477.
  • 3BODY J J,DIEL I J,LICHINITSER M R,et al.Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases[J].Ann Oncol,2003,14 (9):1399-1405.
  • 4HIRAGA T,WILLIAMS P J,MUNDY G R,et al.The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases[J].Cancer Res,2001,61 (11):4418 -4424.
  • 5VOGT U,BIELAWSKI K P,BOSSE U,et al.Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil,epirubicin/cyclophosphamide,epirubicin/paclitaxel,and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid[J].Oncol Rep,2004,12(5):1109-1114.
  • 6YANO S,ZHANG H,HANIBUCHI M,et al.Combined therapy with a new bisphosphonate,minodronate (YM529),and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice[J].Clin Cancer Res,2003,9 (14):5380-5385.

同被引文献8

  • 1Roodman G D. Mechanisms of bone metastasis[J]. N Eng J Med, 2004, 350(16):1655- 1654.
  • 2Yan V, Chow E, Davis L, et al. Pain management in cancer patients with bone metastases remains a challenge[ J ]. J Pain Symptom Mannage, 2004, 27(1):1-3.
  • 3Mystakidou K, Katsouda E, Stathopoulou E, et al. Approaches to managing bone metastases from breast cancer: The role of bisphosphonates [J]. Cancer Treat Rev,2005,31 (4) :303 - 311.
  • 4Body J J, Lichilitser M, T julandin S A, et al. Effect of oral ibandronate versus intravenous( iv. ) zoledronaic acid on markers of bone resorption in patients with breast cancer and bone metastases:result from a comparative phase Ⅲ trail[J]. J Clin Oncol, 2005,23( 16- suppl) : 534.
  • 5Yano S, Zhang H, Hanibuchi M, et al. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice[J]. Clin Cancer Res,2003,9(14) :5380 - 5385.
  • 6Vassiliosv, Chrestine K, Christos C, et al. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologie assessment[J]. Int J Radial Oneol Biol Phys, 2007,67 (1):264-272.
  • 7Bell R, Diel I J, Body J J, et al. Renal safety of ibandronate in patients with bone metastases from breast cancer: phase Ⅲ trail results[J]. Eur J Cancer(suppl), 2004,2(3) : 132.
  • 8Body IJ, DiellJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo - controlled phase Ⅲ studies[J]. BrJ Cancer 2004,90(6):1133- 1137.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部